Trial Profile

A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jul 2025 According to a Jacobio Pharmaceuticals media release, data from this study presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability.
22 Mar 2023 According to Jacobio media release, the phase I dose escalation portion in solid tumors and hematological malignancies is ongoing the USA and China simultaneously. RP2D is expected to be determined in the Q2 of 2023.
23 Aug 2022 According to a Jacobio Pharmaceuticals media release, the recommended Phase II dose (RP2D) will be determined in Q4 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com